| Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers TK Han, WR Proctor, CL Costales, H Cai, RS Everett, DR Thakker Journal of Pharmacology and Experimental Therapeutics 352 (3), 519-528, 2015 | 131 | 2015 |
| Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes TK Han, RS Everett, WR Proctor, CM Ng, CL Costales, KLR Brouwer, ... Molecular pharmacology 84 (2), 182-189, 2013 | 127 | 2013 |
| Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells D Diaz, A Scott, P Carmichael, W Shi, C Costales Mutation Research/Genetic Toxicology and Environmental Mutagenesis 630 (1-2 …, 2007 | 114 | 2007 |
| Direct activation of human phospholipase C by its well known inhibitor u73122 RR Klein, DM Bourdon, CL Costales, CD Wagner, WL White, JD Williams, ... Journal of Biological Chemistry 286 (14), 12407-12416, 2011 | 85 | 2011 |
| Quantitative contribution of six major transporters to the hepatic uptake of drugs:“SLC-phenotyping” using primary human hepatocytes Y Bi, C Costales, S Mathialagan, M West, S Eatemadpour, S Lazzaro, ... Journal of Pharmacology and Experimental Therapeutics 370 (1), 72-83, 2019 | 75 | 2019 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results A Margolskee, AS Darwich, X Pepin, L Aarons, A Galetin, ... European Journal of Pharmaceutical Sciences 96, 610-625, 2017 | 69 | 2017 |
| Moving beyond binary predictions of human drug-induced liver injury (DILI) toward contrasting relative risk potential MD Aleo, F Shah, S Allen, HA Barton, C Costales, S Lazzaro, L Leung, ... Chemical research in toxicology 33 (1), 223-238, 2019 | 55 | 2019 |
| Physiologically‐based pharmacokinetic modeling approach to predict rifampin‐mediated intestinal P‐glycoprotein induction S Yamazaki, C Costales, S Lazzaro, S Eatemadpour, E Kimoto, ... CPT: Pharmacometrics & Systems Pharmacology 8 (9), 634-642, 2019 | 53 | 2019 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across … AS Darwich, A Margolskee, X Pepin, L Aarons, A Galetin, ... European Journal of Pharmaceutical Sciences 96, 626-642, 2017 | 50 | 2017 |
| QSAR modeling of in vitro inhibition of cytochrome P450 3A4 B Mao, R Gozalbes, F Barbosa, J Migeon, S Merrick, K Kamm, E Wong, ... Journal of chemical information and modeling 46 (5), 2125-2134, 2006 | 47 | 2006 |
| Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes Y Bi, RJ Scialis, S Lazzaro, S Mathialagan, E Kimoto, J Keefer, H Zhang, ... The AAPS journal 19, 787-796, 2017 | 45 | 2017 |
| Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling C Costales, J Lin, E Kimoto, S Yamazaki, JR Gosset, AD Rodrigues, ... CPT: pharmacometrics & systems pharmacology 10 (9), 1018-1031, 2021 | 42 | 2021 |
| Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug Y Bi, S Mathialagan, L Tylaska, M Fu, J Keefer, A Vildhede, C Costales, ... Journal of Pharmacology and Experimental Therapeutics 364 (3), 390-398, 2018 | 42 | 2018 |
| Simultaneous assessment of transporter-mediated drug–drug interactions using a probe drug cocktail in cynomolgus monkey RE Kosa, S Lazzaro, Y Bi, B Tierney, D Gates, S Modi, C Costales, ... Drug Metabolism and Disposition 46 (8), 1179-1189, 2018 | 39 | 2018 |
| In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery B Feng, MV Varma, C Costales, H Zhang, L Tremaine Expert opinion on drug discovery 9 (8), 873-890, 2014 | 39 | 2014 |
| Identification of glycochenodeoxycholate 3‐O‐glucuronide and glycodeoxycholate 3‐O‐glucuronide as highly sensitive and specific OATP1B1 biomarkers M Neuvonen, P Hirvensalo, A Tornio, B Rago, M West, S Lazzaro, ... Clinical Pharmacology & Therapeutics 109 (3), 646-657, 2021 | 38 | 2021 |
| A multiplexed HILIC-MS/HRMS assay for the assessment of transporter inhibition biomarkers in phase i clinical trials: isobutyryl-carnitine as an organic cation transporter … L Luo, R Ramanathan, L Horlbogen, S Mathialagan, C Costales, ... Analytical Chemistry 92 (14), 9745-9754, 2020 | 33 | 2020 |
| Biomarker‐informed model‐based risk assessment of organic anion transporting polypeptide 1B mediated drug‐drug interactions E Kimoto, C Costales, MA West, Y Bi, M Vourvahis, A David Rodrigues, ... Clinical Pharmacology & Therapeutics 111 (2), 404-415, 2022 | 31 | 2022 |
| Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs J Lin, E Kimoto, S Yamazaki, M Vourvahis, A Bergman, AD Rodrigues, ... Clinical Pharmacology & Therapeutics 113 (5), 1058-1069, 2023 | 24 | 2023 |
| Application of physiologically based pharmacokinetic modeling in understanding bosutinib drug-drug interactions: importance of intestinal P-glycoprotein S Yamazaki, CM Loi, E Kimoto, C Costales, MV Varma Drug Metabolism and Disposition 46 (8), 1200-1211, 2018 | 24 | 2018 |
